Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
RYTM Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2025 Earnings Call Transcript
Positive11-4
The company shows strong financial performance with a 54% YoY revenue increase and sustainable growth plans for BBS sales. The upcoming launch of IMCIVREE in hypothalamic obesity and positive payer feedback suggest potential market expansion. However, management's lack of clarity on certain aspects and the absence of a go/no-go decision for the PWS Phase III trial may cause some uncertainty. Considering the market cap, the overall sentiment is positive, predicting a 2% to 8% stock price increase over the next two weeks.
Rhythm Pharmaceuticals, Inc. (RYTM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-9
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call summary indicates mixed results. The company has strong financial metrics, with a significant cash runway and international expansion. However, the Q&A section reveals uncertainties in clinical trials and a lack of clear guidance, which could dampen investor sentiment. The equity offering and increased expenses may also weigh on the stock. Overall, the market cap suggests moderate volatility, leading to a neutral prediction for the stock price movement over the next two weeks.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2025 Earnings Call Transcript
Unknown5-9
The earnings call presents a mixed sentiment. The company has positive developments, such as the completion of Phase 2 study enrollment and international expansion, but lacks specific revenue guidance, which is a concern. The Q&A reveals some uncertainties, like the FDA filing process and unclear patient mix insights. However, there are no significant safety issues, and the company is exploring new market opportunities, like China. Considering the market cap, these factors suggest a neutral stock price movement over the next two weeks.
RYTM Slides
RYTM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
